Nilotinib CAS 641571-10-0 AMN 107 Tasigna

Model: C28H22F3N7O
Place of Origin: Shandong,China (Mainland)
Brand: MOSINTER
Molecular Formula: C28H22F3N7O
Content: 99%
Molecular Weight: 529.52
Density: 1.362g/cm3
Specification: CP/USP/EP

inquiry

skype basketAdd to Basket  Edit

Share |

Product Description

Payment & Shipping Terms Supply Capacity
Payment Terms:L/C, T/T, WUProduction Capacity:50 Klogram/Year
Min. Order:10 GramPacking:According to the...
Means of Transport:Ocean, Air, LandDelivery Date:within 7 days

Nilotinib(CAS: 641571-10-0)

Item

Index

Molecular Formula

C28H22F3N7O

Molecular Weight

529.52

Specification

CP/USP/EP

Content

99%

Nilotinib (AMN107, trade name Tasigna), in the form of the hydrochloride monohydrate salt, is a small molecule tyrosine kinase inhibitorapproved for the treatment of imatinib-resistant chronic myelogenous leukemia.

Medical uses

It is FDA- (29 October 2007), EMA- (29 September 2009), MHRA- (19 November 2007) and TGA- (17 January 2008) approved for use as a treatment for Philadelphia Chromosome (Ph+)-positive Chronic myelogenous leukaemia. In June 2006, a Phase I clinical trial found nilotinib has a relatively favorable safety profile and shows activity in cases of CML resistant to treatment with imatinib, another tyrosine kinase inhibitor currently used as a first-line treatment. In that study 92% of patients (already resistant or unresponsive to imatinib) achieved a normal white blood cell counts after five months of treatment. The drug carries a black box warning for possible heart complications. The use of low doses of nilotinib is being investigated for use for Parkinson's and Alzheimer's disease, as well as for ALS, dementia and Huntington's disease. Novartis announced on April 11, 2011 that it is discontinuing a Phase III trial of Tasigna® (nilotinib) for investigational use in the first-line treatment of gastrointestinal stromal tumor (GIST) based on the recommendation of an independent data monitoring committee. Interim results showed Tasigna is unlikely to demonstrate superiority compared to Novartis's Glivec® (imatinib)*, the current standard of care in this setting.

Category: Antineoplastic Drugs API

Related Category: Other Pharmaceutical API  Veterinary Medicine API  Diagnostic Agents API  Vitamin Preparation API  Psychotropic Drugs API 


«
Offline Showroom in USA
QR Code